Assignee
ENZON PHARMACEUTICALS INC
US·36 granted patents·21 pending applications·689 citations·filing 1999–2012
Top patents by PatentIndex Score
57 records- 0197US7087229B2Releasable polymeric conjugates based on aliphatic biodegradable linkersENZON PHARMACEUTICALS INC·Filed 2003·Granted Aug 8, 2006·126 cites·32 claims
- 0296US7737264B2Oligomeric compounds for the modulation HIF-1α expressionENZON PHARMACEUTICALS INC·Filed 2003·Granted Jun 15, 2010·129 cites·35 claims
- 0393US7713738B2Oligomeric compounds for the modulation of survivin expressionENZON PHARMACEUTICALS INC·Filed 2004·Granted May 11, 2010·118 cites·9 claims
- 0493US6777387B2Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the sameENZON PHARMACEUTICALS INC·Filed 2001·Granted Aug 17, 2004·45 cites·18 claims
- 0592US7462627B2Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancersENZON PHARMACEUTICALS INC·Filed 2007·Granted Dec 9, 2008·13 cites·34 claims
- 0692US6720306B2Tetrapartate prodrugsENZON PHARMACEUTICALS INC·Filed 2001·Granted Apr 13, 2004·54 cites·35 claims
- 0791US7365127B2Process for the preparation of polymer conjugatesENZON PHARMACEUTICALS INC·Filed 2005·Granted Apr 29, 2008·10 cites·30 claims
- 0889US7723351B2Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancersENZON PHARMACEUTICALS INC·Filed 2008·Granted May 25, 2010·7 cites·23 claims
- 0989US7671067B2Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecinENZON PHARMACEUTICALS INC·Filed 2007·Granted Mar 2, 2010·6 cites·20 claims
- 1089US7595304B2Polymeric oligonucleotide prodrugsENZON PHARMACEUTICALS INC·Filed 2004·Granted Sep 29, 2009·30 cites·28 claims
- 1189US7273845B2Polymeric prodrugs of vancomycinENZON PHARMACEUTICALS INC·Filed 2003·Granted Sep 25, 2007·21 cites·14 claims
- 1288US8367065B2Targeted polymeric prodrugs containing multifunctional linkersENZON PHARMACEUTICALS INC·Filed 2009·Granted Feb 5, 2013·17 cites·19 claims
- 1388US8048891B2Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecinENZON PHARMACEUTICALS INC·Filed 2010·Granted Nov 1, 2011·5 cites·20 claims
- 1488US7569657B2Methods of preparing polymers having terminal amine groups using protected amine saltsENZON PHARMACEUTICALS INC·Filed 2006·Granted Aug 4, 2009·9 cites·23 claims
- 1587US7863437B2RNA antagonist compounds for the modulation of PIK3CA expressionENZON PHARMACEUTICALS INC·Filed 2008·Granted Jan 4, 2011·6 cites·5 claims
- 1686US6764853B2Method for targeted delivery of nucleic acidsENZON PHARMACEUTICALS INC·Filed 2001·Granted Jul 20, 2004·9 cites·16 claims
- 1785US7332164B2Heterobifunctional polymeric bioconjugatesENZON PHARMACEUTICALS INC·Filed 2003·Granted Feb 19, 2008·15 cites·13 claims
- 1884US7868131B2Methods of preparing polymers having terminal amine groupsENZON PHARMACEUTICALS INC·Filed 2006·Granted Jan 11, 2011·5 cites·24 claims
- 1983US7928095B2Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecinENZON PHARMACEUTICALS INC·Filed 2008·Granted Apr 19, 2011·5 cites·29 claims
- 2081US8785617B2Oligomeric compounds for the modulation of HIF-1A expressionENZON PHARMACEUTICALS INC·Filed 2012·Granted Jul 22, 2014·4 cites·19 claims
- 2181US7462687B2Prodrugs of vancomycin with hydrolysis resistant polymer linkagesENZON PHARMACEUTICALS INC·Filed 2003·Granted Dec 9, 2008·9 cites·28 claims
- 2280US7413738B2Releasable polymeric conjugates based on biodegradable linkersENZON PHARMACEUTICALS INC·Filed 2004·Granted Aug 19, 2008·10 cites·25 claims
- 2379US7301003B2Method of preparing polymers having terminal amine groupsENZON PHARMACEUTICALS INC·Filed 2005·Granted Nov 27, 2007·3 cites·22 claims
- 2478US7939507B2Potent LNA oligonucleotides for the inhibition of HIF-1a expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted May 10, 2011·2 cites·5 claims
- 2574US7989429B2LNA antagonists targeting the androgen receptorENZON PHARMACEUTICALS INC·Filed 2010·Granted Aug 2, 2011·2 cites·10 claims
- 2674US7915401B2Compounds for the modulation of beta-catenin expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted Mar 29, 2011·1 cites·5 claims
- 2773US7846911B2Oligomeric compounds for the modulation of HIF-1alpha expressionENZON PHARMACEUTICALS INC·Filed 2009·Granted Dec 7, 2010·1 cites·9 claims
- 2873US7033583B2Polymeric thiol-linked prodrugsENZON PHARMACEUTICALS INC·Filed 2002·Granted Apr 25, 2006·10 cites·19 claims
- 2972US7642072B2Optimized interferon-beta geneENZON PHARMACEUTICALS INC·Filed 2005·Granted Jan 5, 2010·3 cites·11 claims
- 3064US2010056543A1Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereofENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3161US7625898B2Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereofENZON PHARMACEUTICALS INC·Filed 2008·Granted Dec 1, 2009·0 cites·10 claims
- 3261US7601798B2Methods of preparing polymers having terminal amine groups using protected amine saltsENZON PHARMACEUTICALS INC·Filed 2005·Granted Oct 13, 2009·0 cites·22 claims
- 3361US2011223257A1Releasable fusogenic lipids for nucleic acids delivery systemsENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3461US2009017004A1Polymeric drug delivery systems containing an aromatic allylic acidENZON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3559US2011230420A1Releasable conjugates for nucleic acids delivery systemsENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3659US2009221471A1Prodrugs of vancomycin with hydrolysis resistant polymer linkagesENZON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 3758US8357670B2Oligomeric compounds for the modulation of HIF-1A expressionENZON PHARMACEUTICALS INC·Filed 2012·Granted Jan 22, 2013·0 cites·9 claims
- 3856US2011105413A1Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotidesENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 3954US8039446B2Compounds for the modulation of beta-catenin expressionENZON PHARMACEUTICALS INC·Filed 2010·Granted Oct 18, 2011·0 cites·11 claims
- 4054US7897647B2Releasable polymeric conjugates based on aliphatic biodegradable linkersENZON PHARMACEUTICALS INC·Filed 2006·Granted Mar 1, 2011·0 cites·44 claims
- 4153US2010203066A1Polymeric linkers containing pyridyl disulfide moietiesENZON PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 4253US2009016985A1Polymeric drug delivery system containing a multi-substituted aromatic moietyENZON PHARMACEUTICALS INC·Filed 2008·Application pending·0 cites
- 4352US2011124709A1Rna antagonists targeting gli2ENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4451US7989554B2Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acidENZON PHARMACEUTICALS INC·Filed 2006·Granted Aug 2, 2011·0 cites·27 claims
- 4551US2010056555A1Method of treating ras associated cancerENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4651US2011111044A1Nanoparticle compositions for nucleic acids delivery systemENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4750US6689762B1Composition and methods for treatment of HIV infectionENZON PHARMACEUTICALS INC·Filed 1999·Granted Feb 10, 2004·14 cites·12 claims
- 4850US2011229581A1Releasable cationic lipids for nucleic acids delivery systemsENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
- 4948US2010279408A1Polymeric short interfering rna conjugatesENZON PHARMACEUTICALS INC·Filed 2007·Application pending·0 cites
- 5047US2009202573A1Polymeric conjugates containing positively-charged moietiesENZON PHARMACEUTICALS INC·Filed 2009·Application pending·0 cites
Showing the top 50 of 57 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →